Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000694473 | SCV000822921 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-11-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 2072 of the ATM protein (p.Gly2072Ala). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 572949). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Color Diagnostics, |
RCV001191949 | SCV001359891 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-05-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001191949 | SCV002655364 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-08-09 | criteria provided, single submitter | clinical testing | The p.G2072A variant (also known as c.6215G>C), located in coding exon 42 of the ATM gene, results from a G to C substitution at nucleotide position 6215. The glycine at codon 2072 is replaced by alanine, an amino acid with similar properties. This alteration was detected in 1/5589 German BRCA1/2-negative probands with breast cancer (Hauke J et al. Cancer Med, 2018 04;7:1349-1358). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004569322 | SCV005057102 | uncertain significance | Familial cancer of breast | 2024-01-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004768576 | SCV005377148 | uncertain significance | not provided | 2023-11-12 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with breast cancer (PMID: 29522266); This variant is associated with the following publications: (PMID: 29522266, 23532176) |
Natera, |
RCV000694473 | SCV002081046 | uncertain significance | Ataxia-telangiectasia syndrome | 2021-03-17 | no assertion criteria provided | clinical testing |